Showing 39,241 - 39,260 results of 63,008 for search '(( 09 ((0 decrease) OR (a decrease)) ) OR ( 20 ((we decrease) OR (mean decrease)) ))', query time: 0.93s Refine Results
  1. 39241
  2. 39242
  3. 39243
  4. 39244
  5. 39245
  6. 39246
  7. 39247
  8. 39248
  9. 39249
  10. 39250
  11. 39251
  12. 39252
  13. 39253

    Table 1_Association between body composition in early pregnancy and the risk of gestational diabetes mellitus.docx by Yan Li (23143)

    Published 2025
    “…However, the association between body composition and GDM risk remains unclear. Therefore, we conducted a retrospective cohort study to investigate the relationship between body composition in early pregnancy and the risk of developing GDM.…”
  14. 39254

    SIRT1 inhibition in dissociated E12.5 neocortical neurons enhanced SCPN/CSN subtype refinement, increasing the number of CTIP2-expressing, SATB2-negative neurons at the expense of... by Cameron Sadegh (11378606)

    Published 2021
    “…Data are presented as mean +/- s.e.m. (N = 3; >5,000 nuclei screened per condition from 40 randomly sampled fields at 20x magnification) *P < 0.05; **P < 0.01 (unpaired t-test).…”
  15. 39255
  16. 39256

    Ionosonde spread F and GPS L-band scintillation occurrence during moderate geomagnetic storms near the southern crest of the EIA in Argentina by Gilda González (9246194)

    Published 2020
    “…<div><b><i>This poster was presented in the 20th International Beacon Satellite Symposium (19 – 23 August 2019, University of Warmia and Mazury, Olsztyn, Poland).…”
  17. 39257

    Inhibition of <i>bmm</i> in glia does not alter whole-body triglyceride breakdown. by Lianna W. Wat (8339454)

    Published 2021
    “…(B) Between 12 and 24 hours post-starvation, we observed only a modest reduction in female triglyceride levels post-starvation in all genotypes (<i>repo>UAS-bmm-RNAi</i>, <i>repo-GAL4>+</i>, and <i>+>UAS-bmm-RNAi</i>), and the magnitude of this reduction was similar between genotypes (<i>p</i> = 0.0019, 4.8 × 10<sup>−6</sup>, and 2.0 × 10<sup>−7</sup>, respectively; one-way ANOVA followed by Tukey HSD test). …”
  18. 39258

    Dual Inhibition of Topoisomerase II and Tyrosine Kinases by the Novel Bis-Fluoroquinolone Chalcone-Like Derivative HMNE3 in Human Pancreatic Cancer Cells by Yong-Chao Ma (174419)

    Published 2016
    “…Consistent with cellular apoptosis data, a significant decrease in topoisomerase IIβ activity was noted following treatment with HMNE3 for 24 h. …”
  19. 39259

    Fragmentation patterns for Schisandrin A. by Zhaoping Meng (4875040)

    Published 2025
    “…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”
  20. 39260

    Chemical structure of a lignan. by Zhaoping Meng (4875040)

    Published 2025
    “…Twenty-two differential metabolites (VIP ≥ 1) were identified using untargeted metabolomics. 3 primary metabolites, namely mannose, pyruvate, and shikimic acid, together with 2 secondary metabolites, phenylalanine and mevalonic acid, were observed to decrease. 17 secondary metabolites, including Schisandrin A, Schisandrin B, Schisandrin C, Gomisin D, Gomisin G, Gomisin H, Benzoylgomisin H, Benzoylgomisin O,Angeloylgomisin P, Catechin, Isorhamnetin, Luteolin, Cinnamic acid, Hydroxycinnamic acid, Hexahydrocurcumin, Coniferyl alcohol, Phenylalanine, Terpinolene and Mevalonic acid, exhibited increases in their levels by 10.64, 1.84, 1.40, 1.64, 4.46, 8.18, 1.72, 10.20, 2.08, 1.27, 1.57, 1.18, 2.01, 1.12, 1.88, 1.15, and 3.17-fold, respectively. …”